Literature DB >> 28602044

The dynamic interaction between pain and opioid misuse.

Adrianne R Wilson-Poe1, Jose A Morón1.   

Abstract

In 2014, drug overdose surpassed automobile accidents as the number one cause of accidental death for the first time in the history of the United States. The overdose epidemic is largely driven by opioids, and genuine prescription opioid analgesics play the biggest role in this phenomenon. Despite advancements in abuse deterrent formulations, prescription drug monitoring programmes and clinical assessments for the detection of abuse potential, drug overdoses continue to escalate. The Center for Disease Control has recently issued new guidelines for opioid prescription, yet even these recommendations have their shortcomings. Furthermore, undertreated pain in patients with comorbid substance use disorder poses a major clinical challenge, particularly for patients on opioid replacement therapy. Despite the seemingly obvious interaction between the presence of pain and the abuse of pain-relieving opioids, there is surprisingly little mechanistic data to further our understanding of this vitally important topic. The need for novel pain interventions that minimize abuse liability is critical. Without a fundamental characterization of pain neurobiology and the interaction between chronic pain and the brain's reward system, we are unlikely to make progress in the alleviation of the opioid epidemic. LINKED ARTICLES: This article is part of a themed section on Emerging Areas of Opioid Pharmacology. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.14/issuetoc.
© 2017 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28602044      PMCID: PMC6016619          DOI: 10.1111/bph.13873

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  97 in total

1.  Neuropathic and chronic pain stimuli downregulate central mu-opioid and dopaminergic transmission.

Authors:  Keiichi Niikura; Minoru Narita; Eduardo R Butelman; Mary Jeanne Kreek; Tsutomu Suzuki
Journal:  Trends Pharmacol Sci       Date:  2010-05-12       Impact factor: 14.819

Review 2.  Nonmedical prescription opioid use and mental health and pain comorbidities: a narrative review.

Authors:  Erica Amari; Jürgen Rehm; Elliot Goldner; Benedikt Fischer
Journal:  Can J Psychiatry       Date:  2011-08       Impact factor: 4.356

3.  Cannabinoid-opioid interaction in chronic pain.

Authors:  D I Abrams; P Couey; S B Shade; M E Kelly; N L Benowitz
Journal:  Clin Pharmacol Ther       Date:  2011-11-02       Impact factor: 6.875

4.  Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration.

Authors:  Diana L Cichewicz; Erin A McCarthy
Journal:  J Pharmacol Exp Ther       Date:  2003-03       Impact factor: 4.030

5.  Ethanol dually modulates GABAergic synaptic transmission onto dopaminergic neurons in ventral tegmental area: role of mu-opioid receptors.

Authors:  C Xiao; J-H Ye
Journal:  Neuroscience       Date:  2008-02-06       Impact factor: 3.590

6.  Development and validation of the Current Opioid Misuse Measure.

Authors:  Stephen F Butler; Simon H Budman; Kathrine C Fernandez; Brian Houle; Christine Benoit; Nathaniel Katz; Robert N Jamison
Journal:  Pain       Date:  2007-05-09       Impact factor: 6.961

7.  Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders.

Authors:  Adley Tsang; Michael Von Korff; Sing Lee; Jordi Alonso; Elie Karam; Matthias C Angermeyer; Guilherme Luiz Guimaraes Borges; Evelyn J Bromet; K Demytteneare; Giovanni de Girolamo; Ron de Graaf; Oye Gureje; Jean-Pierre Lepine; Josep Maria Haro; Daphna Levinson; Mark A Oakley Browne; Jose Posada-Villa; Soraya Seedat; Makoto Watanabe
Journal:  J Pain       Date:  2008-07-07       Impact factor: 5.820

8.  Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.

Authors:  S G Kinsey; J Z Long; S T O'Neal; R A Abdullah; J L Poklis; D L Boger; B F Cravatt; A H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2009-06-05       Impact factor: 4.030

9.  Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain.

Authors:  Kevin F Boehnke; Evangelos Litinas; Daniel J Clauw
Journal:  J Pain       Date:  2016-03-19       Impact factor: 5.820

10.  Vital signs: variation among States in prescribing of opioid pain relievers and benzodiazepines - United States, 2012.

Authors:  Leonard J Paulozzi; Karin A Mack; Jason M Hockenberry
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-07-04       Impact factor: 17.586

View more
  12 in total

Review 1.  Determinants of opioid abuse potential: Insights using intracranial self-stimulation.

Authors:  S Stevens Negus; Megan J Moerke
Journal:  Peptides       Date:  2018-11-01       Impact factor: 3.750

2.  Repeated Morphine Produces Sensitization to Reward and Tolerance to Antiallodynia in Male and Female Rats with Chemotherapy-Induced Neuropathy.

Authors:  L P Legakis; S S Negus
Journal:  J Pharmacol Exp Ther       Date:  2018-01-23       Impact factor: 4.030

Review 3.  Interactions between pain states and opioid reward assessed with intracranial self-stimulation in rats.

Authors:  Megan J Moerke; S Stevens Negus
Journal:  Neuropharmacology       Date:  2019-07-01       Impact factor: 5.250

4.  Operant Self-medication for Assessment of Spontaneous Pain Relief and Drug Abuse Liability in Mouse Models of Chronic Pain.

Authors:  David Cabañero; Beltrán Álvarez-Pérez; Elena Martín-García; Rafael Maldonado
Journal:  Bio Protoc       Date:  2022-03-05

5.  The Covid 19 Pandemic Effect on the Epidemiology of Thoracolumbar Fractures Presenting to the Emergency Department in Patients Above 65 years Old.

Authors:  Raphael Lotan; Ilia Prosso; Lev Klatzkin; Oded Hershkovich
Journal:  Geriatr Orthop Surg Rehabil       Date:  2022-04-23

6.  Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Design, Synthesis, and Evaluation of Analogues with Improved Potency and G-protein Activation Bias at the μ-Opioid Receptor.

Authors:  Rachel S Crowley; Andrew P Riley; Amy F Alder; Richard J Anderson; Dan Luo; Sophia Kaska; Pamela Maynez; Bronwyn M Kivell; Thomas E Prisinzano
Journal:  ACS Chem Neurosci       Date:  2020-05-26       Impact factor: 4.418

7.  Identifying individuals with opioid use disorder: Validity of International Classification of Diseases diagnostic codes for opioid use, dependence and abuse.

Authors:  Pooja Lagisetty; Claire Garpestad; Angela Larkin; Colin Macleod; Derek Antoku; Stephanie Slat; Jennifer Thomas; Victoria Powell; Amy S B Bohnert; Lewei A Lin
Journal:  Drug Alcohol Depend       Date:  2021-02-13       Impact factor: 4.492

Review 8.  A Review of the Opioid Epidemic: What Do We Do About It?

Authors:  Edward A Shipton; Elspeth E Shipton; Ashleigh J Shipton
Journal:  Pain Ther       Date:  2018-04-06

9.  Screening tools for detecting problematic opioid use and potential application to community pharmacy practice: a review.

Authors:  Bryn Lindley; Nicholas Cox; Gerald Cochran
Journal:  Integr Pharm Res Pract       Date:  2019-07-19

Review 10.  Does Rebound Pain after Peripheral Nerve Block for Orthopedic Surgery Impact Postoperative Analgesia and Opioid Consumption? A Narrative Review.

Authors:  Olufunke Dada; Alicia Gonzalez Zacarias; Corinna Ongaigui; Marco Echeverria-Villalobos; Michael Kushelev; Sergio D Bergese; Kenneth Moran
Journal:  Int J Environ Res Public Health       Date:  2019-09-05       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.